Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease

Completed

• Conditions: Parkinson's disease; Nervous System Diseases

• Registration Number: ISRCTN59798735
• Lead Sponsor: niversity Medical Center Groningen (UMCG) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05-01
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

1. Early Parkinson's disease patients
2. Hoehn and Yahr Parkinson's Disease Rating Scale (HY) 1 - 2

Exclusion Criteria

Gastrointestinal diseases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
One baseline and one follow-up Positron Emission Tomography (PET) scan (PK11195) and one Magnetic Resonance Imaging (MRI) scan will be performed to assess the reduction of specific cerebral radiotracer uptake (volume of distribution according to Logan graphical method) after celecoxib.

Secondary Outcome Measures

Name	Time	Method
o secondary outcome measures